Jupiter Neurosciences Inc (JUNS)

$JUNS more dilution before rs.

$JUNS Look at the form 4s from today

$JUNS Waiting news..

$JUNS RS VOTE END OF MONTH

$JUNS Time to go back up

$JUNS Some more shares nlught here for me

$JUNS this is such a micro market cap that if and when they succeed in producing/advancing the already FDA approved (next-generation MDMA drug candidate ALA-002) JUNS has the Licensing rights and they have secured $100M funds. When the demand comes flooding so will buyers and the price of the stock to 1000+% in 1 day🤞🏼 Trump signed for human trials to get fast track 1-2 months vs 6-10 months previously. We just need to wait. God speed for their success and no hiccups.

Jupiter Neurosciences (Nasdaq: $JUNS ) adds former White House CEA Acting Chairman Tomas J. Philipson, Ph.D., to its Board as it advances its clinical and strategic growth plans. Jupiter Neurosciences, Inc. (Nasdaq: JUNS) announced the appointment of Tomas J. Philipson, Ph.D., to its Board of Directors, effective June 26, 2026, adding board-level expertise in health economics, regulatory policy, reimbursement strategy, and pharmaceutical value creation. Jupiter Neurosciences is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/jupiter-neurosciences Philipson’s career spans the White House Council of Economic Advisers, FDA and CMS advisory work, the University of Chicago, biopharma consulting, and private-sector health economics leadership. In his statement, Philipson pointed to Jupiter’s in-house JOTROL program, DTC-focused Nugevia portfolio, and the upcoming anticipated acquisition of PharmAla’s ALA-002 as part of what he described as a diversified, revenue-generating, and innovative corporate strategy. Philipson will serve on Jupiter’s Audit and Compensation Committees. The company also disclosed an equity-focused compensation structure intended to align his economic interests with long-term shareholder value. Read the full press release: https://jupiterneurosciences.com/press-releases/?i=167892 Jupiter Neurosciences, Inc. (Nasdaq: JUNS) is a clinical-stage biopharmaceutical company focused on developing therapies for neurological and neurodegenerative disorders. Its lead program is the Phase 2a RESET study in Parkinson’s disease. Learn more at https://jupiterneurosciences.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted JUNS stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $INMB, $ANVS, $AVXL, $ATHA, $XBI

$JUNS when is this company Gunna speak ffs